A Phase 2 interventional study of Aviptadil 67μg and Placebo 0.9% NaCl solution in Covid19, Corona Virus Infection and ARDS, sponsored by Prof. Dr. Jörg Leuppi. Terminated at 2 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-18.
Sponsored by Prof. Dr. Jörg Leuppi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies in COVID-19 with a site in Switzerland — 6 open to participants now, 10 under way, 1 of them phase 3. COVID-19 · Switzerland.
Among the 97 studies in COVID-19 with a site in Switzerland, this one is the 27th largest by enrollment of the 49 interventional ones that give a count, is one of 25 that started in 2021, is one of 8 in phase 2, and was the 42nd registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →6 of the 97 studies in COVID-19 with a site in Switzerland are open now. Recruiting first, the newest first:
Flurin Cathomas · Sites in Switzerland
Ages 18–65
Universitaire Ziekenhuizen KU Leuven · Sites in Switzerland, Belgium, Germany
Ages 18–70
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18–120
Calmy Alexandra · Sites in Switzerland
Ages 16+
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 21 · Phase 4 2
First in 2016; this study’s year is marked. 25 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is below the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 100 across the 49 interventional studies, 425 across the 47 observational. Of the 70 that completed or were terminated, 11 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 97 have an industry lead sponsor. The 10 most frequent:
Prof. Dr. Jörg Leuppi is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Prof. Dr. Jörg Leuppi has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
2 of the studies in COVID-19 with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482138Universitaire Ziekenhuizen KU LeuvenDysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation | 2026-12-31 |
| NCT06716996Flurin CathomasRTMS for the Treatment of Post-COVID Associated Affective Symptoms | 2027-10-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 97 studies in COVID-19 with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The world is currently experiencing a coronavirus (CoV-2) pandemic. A new (SARS)-CoV infection epidemic began in Wuhan, Hubei, China, in late 2019; originally called 2019- nCoV the virus is now known as SARSCoV- 2 and the disease it causes COVID-19. Previous CoV epidemics included severe acute respiratory syndrome (SARS)-CoV, which started in China in 2003 and Middle East respiratory syndrome (MERS)-CoV in the Middle East, which started in 2012. The mortality rates were >10% for SARS and >35% for MERS. The direct cause of death is generally due to ensuing severe atypical pneumonia and ensuing acute respiratory distress syndrome (ARDS). Pneumonia also is generally the cause of death for people who develop influenza, although the mortality rate is lower (1%-3% for the influenza A H5N1 pandemic of 1918-1919 in the United States). Risk factors for a poor outcome of SARS-CoV-2 infection have so far been found to include older age and co-morbidities including chronic cardiovascular and respiratory conditions and current smoking status. In May 2020, the FDA authorized the emergency use of remdesivir for treatment of COVID-19 disease based on topline date of two clinical trials, even though an underpowered clinical trial did not find significant improvement in COVID- 19 patients treated with remdesivir. Nevertheless, remdesivir is the first and so far, only approved treatment for COVID-19. Additionally further trials and clinical observations have not found a significant benefit of other antiviral drugs. Although the results of several studies are still pending, there is still a desperate need for an effective, safe treatment for COVID-19. Aviptadil, which is a synthetic form of Human Vasoactive Intestinal Polypeptide (VIP), might be beneficial in patients at risk of developing ARDS. Nonclinical studies demonstrate that VIP is highly concentrated in the lung, where it reduces inflammation.
About 20% of individuals with Corona Virus disease (COVID-19) experience more severe disease characterized by significant respiratory symptoms including acute respiratory distress syndrome (ARDS). ARDS is a known lethal complication due to its low blood oxygenation levels and may result in organ failure. Until now, there are no specific vaccines or therapeutic drugs targeting SARS-CoV-2, alternative therapeutic interventions are needed to prevent and ameliorate respiratory conditions associated with COVID-19 to effectively reduce mortality and prevent ICU admissions. Aviptadil, which is a synthetic form of Human Vasoactive Intestinal Polypeptide (VIP), might be beneficial in patients at risk of developing ARDS. Nonclinical studies demonstrate that VIP is highly concentrated in the lung, where it prevents N-methyl-D-aspartate (NMDA)-induced caspase-3 activation, inhibits IL-6 and TNFa production and protects against HCl-induced pulmonary edema. Further, in animal model systems of lung injury in mice, rats, guinea pigs, sheep, swine and dogs, Aviptadil was shown to restore barrier function at the endothelial/alveolar interface and to protect the lung and other organs from failure. In Europe, Aviptadil is approved for human use and has been shown to be safe in phase II trials for sarcoidosis, pulmonary fibrosis, bronchospasm, erectile dysfunction as well as in a phase I trial in ARDS in the past two decades. In the US, VIP has been given FDA Orphan Drug Designation for the treatment of ARDS and was admitted to the FDA Corona Virus Technology Accelerator Program. In a phase I trial of Aviptadil performed by Sami Said in the early 2000s, eight patients with severe ARDS on mechanical ventilation were treated with ascending doses of intravenous VIP. Seven patients (88%) were successfully extubated and were alive at the five day time point. Six (75%) left the hospital and one (13%) died of an unrelated cardiac event. A phase II clinical trial using intravenous Aviptadil in patients with COVID-19 infection and ARDS has begun. Further, a phase II/III clinical trial will study the effect of inhaled Aviptadil for the treatment of non-acute lung injury in COVID- 19 and begins in June 2020. In Europe, two phase II trials of Aviptadil have been conducted. Further, studies with healthy volunteers have shown that inhaled Aviptadil is well tolerated with few adverse effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EALI Score:
Modification (for adapting for risk factors for ARDS in SARS-CoV-2 affected patients
Fever > 39°C: 1 point
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
Drug: Aviptadil 67μg
Participants in the control group will receive an Inhalation of 0.9% NaCl solution three times a day for 10 days
Drug: Placebo 0.9% NaCl solution
Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
Patiens will receive Standard care plus 0.9% NaCl solution three times a day for ten days
Time to clinical improvement
Time to clinical improvement of a decrease of at least two points on a seven-point ordinal scale of clinical status or discharged alive from hospital. The seven-point scale consists of the following categories: 1. not hospitalized; 2. hospitalized, not requiring supplemental oxygen; 3. hospitalized, requiring supplemental oxygen; 4. hospitalized, requiring nasal high-flow oxygen therapy, non-invasive mechanical ventilation, or both; 5. hospitalized, intubation and mechanical ventilation; 6. ventilation and additional organ support - pressors, renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO); 7. death
Time frame: Randomization until discharge from hospital but up to maximum 28 days
Frequency of mechanical ventilation
Frequency of Patient who need mechanical ventilation during hospital stay
Time frame: Randomization until discharge from hospital up to maximum 28 days
Oxygen supplementation
Time requiring oxygen supplementation
Time frame: Randomization until discharge from hospital up to maximum 28 days
SaO2
Slope in SaO2
Time frame: Randomization until discharge from hospital up to maximum 28 days
FiO2
Slope in FiO2
Time frame: Randomization until discharge from hospital but up to maximum 28 days
C-reactive Protein
Slope in C-reactive Protein
Time frame: measured at baseline, at least every 7 days and at discharge up to maximum 28 days
Neutrophile
Neutrophile ratio
Time frame: measured at baseline, at least every 7 days and at discharge up to maximum 28 days
lymphocyte
lymphocyte ratio
Time frame: measured at baseline, at least every 7 days and at discharge up to maximum 28 days
Interleukine 6
Interleukine 6 level
Time frame: measured at baseline, at least every 7 days and at discharge up to maximum 28 days
Procalcitonin
Procalcitonin level
Time frame: measured at baseline, at least every 7 days and at discharge up to maximum 28 days
Frequency of Multi organ dysfunction Syndrome (MODS)
Frequency of Patient who showed a multi organ dysfunction Syndrome during Hospital stay
Time frame: Randomization until discharge from hospital up to maximum 28 days
Hospitalization
duration of hospitalization in survivors
Time frame: randomization till discharge of hospital up to 28 days
treatment initiation to death
Time from treatment initiation to death
Time frame: Treatment initiation to death up to maximum 28 days
Blood pressure
Blood pressure will be assessed daily in mmHg
Time frame: Daily until discharge up to maximum 28 days
Heart rate
Heart rate will be assessed daily in bpm
Time frame: Daily until discharge up to maximum 28 days
Respiratory rate
Respiratory rate will be assessed daily in Counts per minute
Time frame: Daily until discharge up to maximum 28 days
Body temperature (auricular) in °C
Body temperature (auricular) will be assessed daily in °C
Time frame: Daily until discharge up to maximum 28 days
Pulse oximetry
Pulse oximetry will be assessed daily in %
Time frame: Daily until discharge up to maximum 28 days
Glasgow Coma Scale
Glasgow Coma Scale will be assessed daily The lowes possible score is 3 = deep coma or death The highest possible score is 15 = Fully awake
Time frame: Daily until discharge up to maximum 28 days
Dispnea and caugh
Visual analogue scale for dyspnea and cough as patient-related outcome parameter
Time frame: Randomization until discharge from hospital up to maximum 28 days
Plan to share: No
Ran from May 2021 to primary completion in Jun 2023, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aviptadil
Prof. Dr. Jörg Leuppi